Pre-made Volagidemab benchmark antibody ( Whole mAb, anti-GCCR/NR3C1 therapeutic antibody, Anti-GCR/GCRST/GR/GRL Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-627

Pre-Made Volagidemab biosimilar, Whole mAb, Anti-GCCR/NR3C1 Antibody: Anti-GCR/GCRST/GR/GRL therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Volagidemab is a G-protein coupled receptors (GPCR) antagonist and was discovered with Xenomouse technology, which recapitulates a human antibody response in the mouse, and the antibody sequences are fully human.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-627-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Volagidemab biosimilar, Whole mAb, Anti-GCCR/NR3C1 Antibody: Anti-GCR/GCRST/GR/GRL therapeutic antibody
INN Name Volagidemab
TargetNR3C1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI Structure4lf3:ED:BA/5xf1:HL:CD/5xez:CD:HL/4ers:HL
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAmgen;REMD Biotherapeutics
Conditions Approvedna
Conditions ActiveType 1 diabetes mellitus;Type 2 diabetes mellitus;Metabolic disorders;Glucose intolerance
Conditions Discontinuedna
Development Techna